InflaRx N.V.
NASDAQ:IFRXBiotechnology
-$0.02 today
- Market cap
- $163.58M
- Beta
- 2.44
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.59
Volume 3.05M
Average 1.80M
IFRX Sales of Investments
Cash received from selling or redeeming investments.
InflaRx N.V.NASDAQ: IFRX
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments declines year over year
Q1 FY2026 sales of investments of €8.4M fell 52.5% year over year, behind the -49.0% change in trailing-twelve-month sales of investments. Sequentially, it fell 56.3% from the prior quarter. Over 3 fiscal years it compounded at -17.3% a year.
Context
- Sales of investments amounted to 161936.0% of revenue in FY2025, up 109006.4 pp from a year earlier.
- Sales of investments increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -52.5% toward the trailing-twelve-month pace of -49.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
EUR · from the cash flow
- Latest · FY2025
- 47.5M EUR
- Year-over-year change
- -45.9%
- 4-year CAGR
- -9.8%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 47.5M | -45.9% |
| FY2024 | 2024-12-31 | 87.75M | +1.5% |
| FY2023 | 2023-12-31 | 86.44M | +2.9% |
| FY2022 | 2022-12-31 | 84M | +17.3% |
| FY2021 | 2021-12-31 | 71.6M | — |
Sales of Investments vs competitors
How IFRX compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -49.0% is the 4th highest of 7, against a peer median of -25.9%.
- Sales of investments amounts to 130343.0% of revenue for IFRX, versus a peer median of 25095.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $263.81M USD | -56.8% | +18.0% | 264.9% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $103.87M USD | +49.8% | — | — |
| LTM Mar 2026 | $87.02M USD | +2.3% | -1.6% | 45798.4% | |
| LTM Mar 2026 | $43.92M USD | -54.1% | -43.1% | 4391.5% | |
| FY2025 | $39.95M USD | +216.4% | +5.0% | 62417.2% | |
| LTM Mar 2026 | €38.23M EUR | -49.0% | -17.3% | 130343.0% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $35M USD | — | — | — |
IMAImageneBio Inc | LTM Mar 2026 | $4.82M USD | -106.7% | -56.4% | — |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding IFRX) | — | -25.9% | -1.6% | 25095.0% | |
Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (45.63M) | (29.48M) | (42.67M) | (46.06M) | (43.83M) |
| Depreciation & Amortization | 669.43K | 596.6K | 567.78K | 485.11K | 402.93K |
| Deferred Income Tax | 1.16M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.33M | 6.04M | 3.41M | 4.07M | 0 |
| Change in Working Capital | 1.54M | (9.77M) | 1M | (2.28M) | 4.66M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 2.12M |
| Inventory | 0 | 0 | (11.37M) | 4.47M | 6.63M |
| Accounts Payables | 316.11K | (3.52M) | 0 | 0 | (5.76M) |
| Other Working Capital | 1.22M | (6.25M) | 12.37M | (6.75M) | 1.68M |
| Other Non-Cash Items | (2M) | (1.13M) | (131.29K) | (4.76M) | 4.84M |
| Operating Cash Flow | (39.94M) | (33.74M) | (37.81M) | (48.56M) | (33.92M) |
| Capital Expenditures | (37.78K) | (162.39K) | (81.1K) | (46.87K) | (111.13K) |
| Acquisitions (Net) | 37.78K | (19.52M) | 0 | 0 | 0 |
| Purchases of Investments | (97.52M) | (64.47M) | (104.05M) | (35.34M) | (44.28M) |
| Sales of Investments | 71.6M | 84M | 86.44M | 87.75M | 47.5M |
| Other Investing Activities | (37.78K) | 19.52M | 0 | 1 | (3) |
| Investing Cash Flow | (25.95M) | 19.36M | (17.7M) | 52.36M | 3.11M |
| Debt Repayment | (360.64K) | (364.43K) | (373.98K) | (388.11K) | (357.58K) |
| Common Stock Issued | 65.14M | 2.35M | 56.48M | 1.1M | 32.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.2M) | (47.74K) | (3.12M) | (323.73K) | 14.11K |
| Financing Cash Flow | 61.58M | 1.94M | 52.99M | 386.45K | 32M |
| Effect of Forex Changes | 4.59M | 2.46M | (974.1K) | 1.41M | (1.37M) |
| Net Change in Cash | 281.31K | (9.98M) | (3.5M) | 5.61M | (179.66K) |
| Free Cash Flow | (39.97M) | (33.91M) | (37.89M) | (48.6M) | (34.03M) |
InflaRx N.V.
NASDAQ:IFRX
Intrinsic Alpha fair value
Locked
Current Price
$1.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.